Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.545
-0.015 (-0.96%)
Apr 24, 2026, 11:02 AM EDT - Market open
Lineage Cell Therapeutics Employees
As of December 31, 2025, Lineage Cell Therapeutics had 77 total employees, including 70 full-time and 7 part-time employees. The number of employees did not change compared to the previous year.
Employees
77
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$189,039
Profits / Employee
-$825,104
Market Cap
384.84M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 77 | 0 | - | 72 | 5 |
| Dec 31, 2024 | 77 | 2 | 2.67% | 70 | 7 |
| Dec 31, 2023 | 75 | -3 | -3.85% | 68 | 7 |
| Dec 31, 2022 | 78 | 17 | 27.87% | 70 | 8 |
| Dec 31, 2021 | 61 | 6 | 10.91% | 57 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Vanda Pharmaceuticals | 533 |
| Rocket Pharmaceuticals | 202 |
| Neurogene | 131 |
| Enanta Pharmaceuticals | 120 |
| Neumora Therapeutics | 96 |
| Century Therapeutics | 78 |
| Assembly Biosciences | 73 |
LCTX News
- 11 days ago - Lineage Announces Formation of Scientific Advisory Board - Business Wire
- 4 weeks ago - Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease - Business Wire
- 7 weeks ago - Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - Business Wire
- 3 months ago - Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience - Business Wire
- 3 months ago - Lineage Cell Therapeutics Issues Letter to Stockholders - Business Wire
- 6 months ago - Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 6 months ago - Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 - Business Wire